Name: | Description: | Size: | Format: | |
---|---|---|---|---|
578.14 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Spray-drying is proposed in this work as the technique to produce konjac
glucomannan microparticles aimed at an application in lung tuberculosis therapy.
Microparticles were developed to provide direct lung delivery of an association of two
first-line antitubercular drugs, isoniazid and rifabutin, by inhalation. Mannitol or leucine
were incorporated as spray-drying excipients to verify their effect on the final properties of
drug-loaded konjac glucomannan microparticles. The obtained results indicate that
konjac glucomannan is a suitable material for the preparation of inhalable microparticles
for antitubercular therapy upon processing by spray-drying. The incorporation of
excipients revealed no benefit on the characterised properties. Isoniazid and rifabutin
were mostly associated to microparticles with success (efficiencies of 88-104%).
However, the presence of mannitol was found to decrease the capacity to associate
isoniazid (efficiency of 43%). The excipients further promoted the acceleration of drug
release. Moreover, general absence of toxicity was observed for microparticles in Calu-3
and A549 cells, with cell viabilities above 70%. The results of the work suggest that
microparticles composed only of KGM display the most appropriate characteristics.
Description
Keywords
Antitubercular drugs Konjac glucomannan microparticles Pulmonary delivery Spray-drying
Citation
Publisher
Elsevier